InterAx Biotech and GPCR Therapeutics Inc collaborate for the identification of compounds with superior biological properties targeting GPCR heteromers using the InterAx systems biology platform
Seoul, South Korea and Villigen, Switzerland – 9th of December 2019
InterAx Biotech AG announced today that it has entered an agreement with GPCR Therapeutics, a biopharmaceutical company focusing on developing drugs targeting disease-specific GPCR heterodimers. “The long-standing in-house expertise on the biology of GPCR heteromers and chemokines at InterAx and the cutting-edge approach of GPCR Therapeutics in targeting relevant heteromers in cancer has resulted in an exciting collaboration. Our unique computational approach to characterize specific signaling patterns of relevant GPCR heteromers will help to identify compounds with superior biological properties”, says Maria Waldhoer, CSO at InterAx. “We are also delighted to be working with an uprising biopharmaceutical company in South Korea, as we are for the first time introducing our platform beyond European borders.”
“We are excited to have the opportunity to partner with InterAx to prioritize drug candidates targeting GPCR heteromers. We hope that combining our innovative platform to target cancer-specific GPCR heteromers with InterAx systems biology modeling will ultimately lead to major discoveries that will benefit patients,” says Dr. Dong Seung Seen, the CEO of GPCR Therapeutics, Inc.
InterAx Biotech AG is pioneering computational pharmacology for drug discovery. The Swiss company is uniquely positioned to assist drug candidate design and selection for G protein-coupled receptors in collaborative projects with Biotech and Pharma companies. InterAx applies mathematical models and simulations to in-house derived bioanalytical data in order to address the complexity of drug-induced cellular signaling mechanisms.
For more information, please visit www.interaxbiotech.com.
About GPCR Therapeutics
GPCR Therapeutics Inc. is a biopharmaceutical company focusing on developing drugs targeting disease-specific GPCR heteromers. The diversity of GPCR heterodimerizations and their modes of action represent an unprecedented challenge and opportunity to discover novel drug targets and develop new drugs with higher specificity and less side effects. By taking novel approaches to targeting GPCR heteromers, the south Korean company is developing innovative pharmaceuticals to address unmet medical needs.
For more information, please visit www.gpcr.co.kr.